Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 2000 of 3499 entries
View as:

Sunitinib Malate in Treating Patients With Recurrent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00388037 Org: User:
Start: 01/31/07 End: 01/31/12 Due: 01/31/13

Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02810418 Org: User:
Start: 08/03/16 End: 06/22/21 Due: 06/22/22

Vaccine Therapy in Treating Patients With Metastatic Melanoma

Phase: N/A Priority: Normal
NCT ID: NCT00019734 Org: User:
Start: 07/31/99 End: 05/31/03 Due: 05/31/04

MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00089076 Org: User:
Start: 06/30/04 End: 10/31/09 Due: 10/31/10

RO4929097 and Letrozole in Treating Post-Menopausal Women With Hormone Receptor-Positive Stage II or Stage III Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01208441 Org: User:
Start: 11/30/10 End: - Due: -

Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01330173 Org: User:
Start: 12/31/10 End: 11/30/14 Due: 11/30/15

T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT03602612 Org: User:
Start: 09/14/18 End: 04/21/26 Due: 04/21/27

Immersive Virtual Reality (VR) at the Time of Clinical Evaluation to Improve Psychological Distress and Anxiety in Primary Brain Tumor (PBT) Patients

Phase: N/A Priority: Normal
NCT ID: NCT04301089 Org: User:
Start: 03/18/21 End: 02/04/25 Due: 02/04/26

The Incidence of Breast and Other Cancers Among Female Flight Attendants

Phase: N/A Priority: Normal
NCT ID: NCT00342407 Org: User:
Start: 11/06/01 End: 04/09/20 Due: 04/09/21

Development of Patient-Reported Outcome Measures Assessing Tumor-Related Disfigurement and Appearance Concerns in Neurofibromatosis Type 1

Phase: N/A Priority: Normal
NCT ID: NCT06880991 Org: User:
Start: 04/29/25 End: 03/31/27 Due: 03/31/28

Collecting Solid Tumor Tissue to Identify New Treatments

Phase: N/A Priority: Normal
NCT ID: NCT01658917 Org: User:
Start: 07/24/12 End: 10/23/17 Due: 10/23/18

Intensity-Modulated Radiation Therapy and Paclitaxel With or Without Pazopanib Hydrochloride in Treating Patients With Anaplastic Thyroid Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01236547 Org: User:
Start: 10/28/10 End: 05/20/22 Due: 05/20/23

Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01859182 Org: User:
Start: 01/31/13 End: 05/31/13 Due: 05/31/14

Clinical Evaluation of a Laser Heated, Fiberoptic-Coupled Radiation Dose Verification System

Phase: N/A Priority: Normal
NCT ID: NCT00026871 Org: User:
Start: 07/31/97 End: 05/31/06 Due: 05/31/07

Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults

Phase: N/A Priority: Normal
NCT ID: NCT04530565 Org: User:
Start: 01/25/21 End: 07/01/28 Due: 07/01/29

Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases

Phase: N/A Priority: Normal
NCT ID: NCT01095523 Org: User:
Start: 01/14/10 End: 02/09/12 Due: 02/09/13

Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00027872 Org: User:
Start: 10/31/01 End: 01/31/09 Due: 01/31/10

Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT00077467 Org: User:
Start: 01/31/04 End: - Due: -

Rebeccamycin Analogue in Treating Children With Solid Tumors or Non-Hodgkin's Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT00006102 Org: User:
Start: 07/31/00 End: - Due: -

A Phase II Study of Bintrafusp Alfa (M7824) in Checkpoint Inhibitor Naive and Refractory Subjects With Urothelial Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04501094 Org: User:
Start: 10/26/20 End: 10/13/21 Due: 10/13/22

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06253520 Org: User:
Start: 05/16/24 End: 06/15/33 Due: 06/15/34

Treatment of Patients With Cancer With Genetically Modified Salmonella Typhimurium Bacteria

Phase: N/A Priority: Normal
NCT ID: NCT00004988 Org: User:
Start: 03/31/00 End: 10/31/02 Due: 10/31/03

Vaccine Therapy With or Without Docetaxel in Treating Patients With Metastatic Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00045227 Org: User:
Start: 08/31/02 End: 10/31/07 Due: 10/31/08

Inotuzumab Ozogamicin and Blinatumomab in Treating Patients With Newly Diagnosed, Recurrent, or Refractory CD22-Positive B-Lineage Acute Lymphoblastic Leukemia

Phase: N/A Priority: Normal
NCT ID: NCT03739814 Org: User:
Start: 05/08/19 End: 02/01/26 Due: 02/01/27

Testing the Addition of a New Anti-cancer Drug, Radium-223 Dichloride, to the Usual Treatment (Cabozantinib) for Advanced Renal Cell Cancer That Has Spread to the Bone, RadiCaL Study

Phase: N/A Priority: Normal
NCT ID: NCT04071223 Org: User:
Start: 07/29/20 End: 10/01/25 Due: 10/01/26